Teva’s well-traveled asthma drug comes through in Phase III – FierceBiotech


Globes

Teva's well-traveled asthma drug comes through in Phase III
FierceBiotech
The drug, which works by blocking the interleukin-5 pathway, met its primary endpoints in two Phase III studies on patients with inadequately controlled asthma and elevated levels of inflammatory white blood cells, Teva said. In 12-month data from more
Teva finds positive results in advanced trials for asthma drugReuters
Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical StudiesRTT News
Teva stakes its claim to the asthma antibody marketPMLiVE
Business Wire (press release) –Globes
all 18 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.